Moreover, existing research has demonstrated that S100A8/A9-neutralizing antibodies exhibit promising therapeutic effects in animal models of myocardial infarction, idiopathic pulmonary fibrosis, ischemia-reperfusion-induced lung injury, melanoma, and atopic dermatitis (Li et al., 2019; Araki et al., 2021; Nakata et al., 2022; Kinoshita et al., 2019; Gohara et al., 2025). Here, S100A8 is linked to atopic eczema.